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Abstract
Background: Post-transcriptional regulation by microRNAs is recognized as one of the major pathways for the
control of cellular homeostasis. Less well understood is the transcriptional and epigenetic regulation of genes
encoding microRNAs. In the present study we addressed the epigenetic regulation of the miR-181c in normal
and malignant brain cells.
Methods: To explore the epigenetic regulation of the miR-181c we evaluated its expression using RT-qPCR
and the in vivo binding of the CCCTC-binding factor (CTCF) to its regulatory region in different glioblastoma
cell lines. DNA methylation survey, chromatin immunoprecipitation and RNA interference assays were used to
assess the role of CTCF in the miR-181c epigenetic silencing.
Results: We found that miR-181c is downregulated in glioblastoma cell lines, as compared to normal brain
tissues. Loss of expression correlated with a notorious gain of DNA methylation at the miR-181c promoter
region and the dissociation of the multifunctional nuclear factor CTCF. Taking advantage of the genomic
distribution of CTCF in different cell types we propose that CTCF has a local and cell type specific regulatory
role over the miR-181c and not an architectural one through chromatin loop formation. This is supported by
the depletion of CTCF in glioblastoma cells affecting the expression levels of NOTCH2 as a target of miR-181c.
Conclusion: Together, our results point to the epigenetic role of CTCF in the regulation of microRNAs
implicated in tumorigenesis.
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Background
MicroRNAs (miRNAs) are small non-coding RNAs that
participate in the control of many cellular processes
such as stress response, cell differentiation, cell-cycle
regulation, stem cell biology, apoptosis among many
others [1]. MicroRNAs exert their regulatory effect
post-transcriptionally by inducing RNA degradation or
translation inhibition, and their expression can be
deregulated in cancer by genetic and epigenetic mecha-
nisms [2–4]. MicroRNAs can also affect gene expres-
sion of many genes by direct regulation of the
epigenetic machinery. For example, microRNAs like
miR-101, miR-205 and miR-26a regulate chromatin
modifiers in cancer such as the Polycomb associated
histone methyltransferase EZH2 [2, 3]. The DNA
methylation maintenance enzyme Dnmt1 is regulated
in different cell- types by the miR-126 and miR-152, as
well as the de novo methyltransferases Dnmt3a and
Dnmt3b by the miR-29 family members miR-29a, −29b
and -29c [5]. Overexpression of miR-29a, −29b and -29c
cause abnormal downregulation of the Dnmt3a and
Dnmt3b, which is associated with development of lung
cancer and acute myeloid leukemia [6, 7].
DNA methylation can regulate microRNAs gene ex-
pression in cancer [8]. In particular, repression of gene
expression by DNA methylation of promoter associ-
ated CpG islands has been reported for several micro-
RNAs in glioblastoma cells like miR-211, miR-204,
miR-145, miR-137 among others [9–12]. For example,
miR-145 was shown to be downregulated in glioblast-
oma cells and low expression of miR-145 was found to
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be correlated with poor prognosis in patients [11].
Overexpression of miR-145 reduced cell proliferation, mi-
gration and invasion in glioblastoma cells by suppressing
SOX9 and ADD3 [13]. Thus, DNA methylation of CpG-
rich microRNAs promoters in glioblastoma cells seems to
be an important process for tumour development and
maintenance.
CTCF is a ubiquitous, highly-conserved 11-zinc finger
nuclear protein [14, 15], which is subjected to different
post-translational modifications [16, 17] and has been
implicated in a broad range of functions including
higher-order chromatin organization by favoring inter-
and intra-chromosomal interactions [18–20]. The com-
binatorial usage of different zinc-fingers confers CTCF
the capacity to bind complex sequences, interact with
other proteins and with ncRNAs [14, 21–23]. CTCF is
also important to maintain, CpG-rich promoter regions
of tumour suppressor genes, like BRCA1, retinoblast-
oma, and others, in an unmethylated state [24, 25]. Im-
portantly, DNA methylation can affect CTCF binding in
part because of the presence of CpGs in the CTCF bind-
ing motif [26]. For example, increased methylation at
the promoter of the brain-derived neurotrophic factor
(BDNF) triggered the dissociation of CTCF which re-
sulted in gene silencing [27]. In fact 41 % of cell-type
specific CTCF binding sites show differential DNA
methylation [28].
In addition, several reports have implicated CTCF in
the regulation of microRNAs expression [29]. MiR-125b
expression is decreased in breast cancer, partly, through
CTCF dissociation from its promoter region [30]. In
addition, ERα positive breast cancer cells overexpress
miR-375 concomitantly with promoter DNA hyperme-
thylation and CTCF depletion [31]. Furthermore, CTCF
and pluripotency maintenance factors are depleted in
the miR-290 regulatory region in differentiated embry-
onic stem cells, together with increased DNA methyla-
tion and deposition of the repressive histone mark
H3K27me3 [32].
The miR-181c is a member of the miR-181 family of
microRNAs involved in the development of glioblastoma
multiforme (GBM), which is one of the most frequent
and malignant primary brain tumours [33, 34]. MiR-181c
is downregulated in GBM, and its expression levels cor-
relate with tumour progression, suggesting that its epi-
genetic regulation could be affected [33]. In contrast,
miR-181c is overexpressed in gastric cancer, skin basal
cell carcinoma, and in osteosarcomas [35–37].
Here we explored the epigenetic regulatory processes
responsible for the deregulation of miR-181c in glioblast-
oma cells; in particular, we asked whether the nuclear
factor CTCF participates in its epigenetic regulation. We
first confirmed that miR-181c is differentially expressed
in glioblastoma cell lines. We analyzed ChIP-seq data
sets from different cell-types and identified a DNA
region located in the 5′ non-coding region of the miR-
181c enriched in histone marks characteristic of pro-
moter regions. We confirmed binding of CTCF to the
promoter region of miR-181c in the glioblastoma cell
line U87MG and K562 cells. In contrast, CTCF does not
bind the promoter region of the aggressive glioblastoma
cell line T98G. Absence of CTCF correlates with gain of
DNA methylation and miR-181c downregulation. Fur-
thermore, we show that depletion of CTCF in glioblast-
oma cells affects the expression levels of NOTCH2 a
target of miR-181c. Together, these results implicate
CTCF and DNA methylation in the epigenetic regulation
of miR-181c in cancer cells.
Methods
Cell culture
K562 human erythroleukemic cells were cultured in
ISCOVE medium (Invitrogen). K562 cells (K562 ATCC®
CCL-243™) were provided by Gary Felsenfeld (National
Institutes of Health, Bethesda, Maryland, US); human
glioblastoma-astrocytoma grade IV U87MG cells (U87MG
ATCC® HTB-14™), human glioblastoma multiforme T98G
cells (T98G ATCC® CRL-1690™) and human acute T cell
leukemia Jurkat cells (Jurkat ATCC® TIB-152™) were cul-
tured in RPMI-1640 medium (Invitrogen); all media con-
tained 10 % (v/v) fetal bovine serum (FBS) and 1 %
penicillin/streptomycin. T98G, U87MG and Jurkat cells
were provided by Manel Esteller (Centro Nacional de
Investigaciones Oncológicas (CNIO) and Cancer Epi-
genetics and Biology Program (PEBC), Spain). All cell
lines were purchased from the American Type Culture
Collection (Manassas, VA) and were previously authen-
ticated by STR profiling. Cells were maintained at 37 °C
in a humidified 5 % CO2-containing atmosphere. Hu-
man lymphocytes were obtained from peripheral blood
of a healthy donor, isolated with Ficoll-Paque Plus
(Amersham) following the manufacturer’s instructions.
Written informed consent was obtained from this
healthy donor.
Quantitative real time PCR
Total RNA from Human Hypothalamus and Orbital
Frontal Cortex were purchased from Ambion (First
Choice® Total RNA AM6786 and AM6864). Total RNA
was extracted from lymphocytes, K562, Jurkat, U87MG
and T98G cells with TRIzol Reagent (Invitrogen) accord-
ing to manufacturer’s instructions. RNAs were treated
with DNase I (RQ1, Promega) followed by Random Pri-
mer cDNA generation from 1 μg DNase I treated RNA
(Reverse Transcription System, Promega). Real-Time
quantitative PCR (qPCR) was carried out with SYBR
Green (Sigma) and specific primers for primiR-181c (For-
ward: 5′-CCCATCTCAGCCTCCTAAGT-3′ and Reverse:
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5′-GACCAACCTGAGCAACATAG-3′), NOTCH2 (For-
ward: 5′-CCTTCCACTGTGAGTGTCTGA-3′ and Re-
verse: 5′- AGGTAGCATCATTCTGGCAGG-3′) and
GAPDH as an endogenous normalization control (For-
ward: 5′-CCACTCCTCCACCTTTGAC-3′ and Reverse:
5′-ACCCTGTTGCTGTAGCCA-3′). In order to analyze
miR-181c mature transcript levels, first strand cDNA was
generated using Taqman® MicroRNA Reverse Transcrip-
tion Assay (Applied Biosystems) with specific primers pro-
vided by the manufacturer and U6 RNA was used as an
endogenous normalization control. MiR-181c mature
transcript levels were measured with Taqman® MicroRNA
Assay primers (Applied Biosystems). The qPCR reac-
tions were carried out in the StepOne detection system
(Applied Biosystems) at 95 °C for 2 min, followed by 40
two-step cycles of 95 °C for 30 s and 60 °C for 45 s,
triplicates were made for each sample. Relative RNA
levels were calculated using the comparative ΔΔCt method.
Significant differences on gene expression were evaluated
by a t-Student test.
DNA sodium bisulfite conversion
Genomic DNA was extracted from indicated cells by
phenol-chloroform technique, and 1.5 μg were cut with
HindIII previous to bisulfite conversion. Bisulfite conver-
sion was performed as described previously [38]. Specific
primers for converted promoter region were used to
generate PCR product (Forward: 5′-GTTTTAGATAGA
GGGGTGGG-3′ and Reverse: 5′- CAATCCTCAAAAAA
CCCAACTC-3′). PCR products were cloned in pGEMT-
easy (Promega) followed by sequencing with Sp6 primer.
Culture recuperation after transformation for plasmid en-
richment was carried out at 30 °C to avoid recombination
as much as possible.
Chromatin immunoprecipitation assay
The ChIP assay was performed as previously reported
with 4 μg of antibody against CTCF (Millipore 07–729)
[38]. Immunoprecipitated DNA was evaluated by PCR




3′ and Reverse: 5′-CAAGCCAAGCAGTGACGAC-3′)
regions, and Igf2/H19 Differential Methylation Region
(DMR) as a positive control (Forward: 5′-CAGGCTCC
CCCAAAATCTA-3′ and Reverse: 5′-GGGAACATAG
AGAAAGAGG-3′).
CTCF knockdown with lentivirus expressing shRNAi
CTCF knockdown was performed essentially as de-
scribed [39]. HEK293FT cells were used to produce
pLL3.7 control and CTCF shRNAi (5′-GGACAGTGTT
TGACAACTAA-3′) lentiviruses with generation III
packaging vectors. pLL3.7 and shRNAi CTCF plasmid
were kindly provided by Joaquín Espinosa [39]. For the
tetracycline inducible system the pTRIPZ lentiviral vec-
tor (Open Systems) was used with shRNAi (5′-AGGAC
AGTGTTGACAACTA-3′) targeting CTCF. U87MG
cells were transduced with virus for 8 h in the presence
of polybrene (8 μg/ml; Sigma). Cultures were then se-
lected for 3–4 days with puromycin (5 μg/ml; Sigma)
and then harvested for the experiments detailed in this
article. Doxycycline induction was carried out with
2 μg/ml for 72 h, and cells were harvested for the cor-
responding experiments.
Bioinformatic analysis
All ChIP-seq and RRBS data was downloaded from the
Analysis/Data hub from the ENCODE project (https://
genome.ucsc.edu/ENCODE/analysis.html) and displayed
on the IGV genome browser (https://www.broadinstitu-
te.org/igv/node/250). CTCF Motif analysis was performed
with JASPAR using the human motif as query (http://jas-
par.genereg.net/). CpG islands were downloaded from the
UCSC genome browser hg19 (https://genome.ucsc.edu/).
In situ Hi-C data from GM12878 cell line at 5 kb reso-
lution was analyzed by using the JuiceBox software
(http://www.aidenlab.org/juicebox/).
Results
Differential expression of miR-181c in brain and human
glioblastoma cells
The human miR-181c is frequently downregulated in
Glioblastoma Multiforme (GBM) and its downregulation
has been linked to tumour progression [33]. However,
the mechanisms controlling its expression are unknown.
To identify the regulatory region of miR-181c we ana-
lyzed ChIP-seq data for the promoter-associated histone
marks H3K4me3 and H3K27ac generated by ENCODE
in the erythroleukemic K562 cell line. We identified a
DNA region occupied by H3K4me3 and H3K27ac lo-
cated 2 k bases (kb) upstream of the sequence corre-
sponding to the mature miR-181c (Fig. 1a and
Additional file 1: Figure S1). This DNA region was pre-
viously reported to act as a promoter of miR-181c [40].
The identified region overlaps with a CpG Island of
0.5 kb containing a CTCF binding motif. Indeed, ChIP-
seq data shows that CTCF binds the promoter region
(Fig. 1a). Since CTCF binds to a CpG rich region in the
promoter of miR-181c we hypothesized that DNA
methylation and CTCF could be critical regulators of
miR-181c expression in glioblastoma.
As a first step to uncover the mechanisms controlling
miR-181c we first evaluated transcript levels for the pri-
miR-181c and mature miR-181c by RT-qPCR in two
glioblastoma cell lines T98G and U87MG, erythroleuke-
mic K562 cells, lymphoblastic Jurkat cells, peripheral
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blood lymphocytes, frontal cortex and hypothalamus-
derived primary cells (Fig. 1b and c). The highest level of
expression of the primiR-181c and the mature miR-181c
transcript were found in cells from the frontal cortex
and hypothalamus, which is consistent with previous re-
ports showing that miR-181c, is mainly expressed in
brain cells in human, mouse and rat (Expression Atlas
EMBL-EBI). Intermediate levels of expression were
found in U87MG glioblastoma cell line, and very low
levels in the aggressive glioblastoma cell line T98G and
the rest of the analyzed cells (Fig. 1b and c). Thus miR-
181c is expressed at low levels in glioblastoma cell lines
as compared with brain primary cells.
Low levels of miR-181c in glioblastoma cells correlate
with DNA hypermethylation of its promoter region
In order to characterize the DNA methylation profile of
the miR-181c promoter region we performed DNA bi-
sulfite conversion coupled to sequencing in T98G and
U87MG glioblastoma cell lines, K562 cells and primary
lymphocytes (Fig. 2a). The highest DNA methylation
levels of the miR-181c promoter, with 86 % of methyl-
ated CpGs, were found in T98G (Fig. 2a). Intermediate
DNA methylation, with 47 % of methylated CpGs, was
found in U87MG. The promoter region was almost
unmethylated, with 0.6 and 5 % of methylated CpGs, in
K562 cells and lymphocytes, respectively (Fig. 2a).
Hypermethylation of the miR-181c promoter region
correlates with the low level of transcript detected in
T98G cells. A 2-fold increase in the expression of the
primiR-181c in U87MG cells, as compared with T98G
cells, correlates with a 50 % reduction in the methyla-
tion of the promoter. Low levels of expression of miR-
181c and primiR-181c do not correlate with absence of
DNA methylation in K562 cells and lymphocytes. This
is probably due to the tissue-specific expression of the
miR-181c and the absence in K562 cell of a particular
set of transcription factors and co-factors needed for
miR-181c gene transcription.
DNA hypermethylation of promoter regions of micro-
RNAs has been linked to transcriptional repression [8].
To determine if the hypermethylation of the promoter
region of miR-181c cells promotes transcriptional re-
pression, we treated T98G cells with the DNA methyla-
tion inhibitor 5-aza-2′-deoxycytidine (5-azadC) for 72 h



































































































Fig. 1 CTCF binds to the promoter of miR-181c. a IGV genome browser screenshot for ChIP-seq data of H3K4me3, H3K27ac, CTCF and Rad21 from
K562 cells and Reduced Representation Bisulfite Sequencing (RRBS) data from the same cell line. Green bars, 0 % molecules sequenced are methylated;
Yellow bars, 50 % molecules are methylated; Red bars, 100 % molecules sequenced are methylated. CTCF binding motif with the highest score
is shown with reference to one CpG island. The region depicted is chr19:13,982,729-13,985,645. Data was downloaded from the Analysis/Data
hub by the ENCODE project. b primiR-181c expression levels in different cells measured by RT-qPCR with SYBR Green. c miR-181c expression
levels in different cells measured by Taqman assay
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primiRNA-181c and mature miR-181c. To confirm these
results we performed DNA bisulfite genomic DNA con-
version and sequencing in T98G genomic DNA previ-
ously treated with 5-azadC. More than 40 % of the CpGs
are demethylated, and of note, the CTCF binding site
seems preferentially unmethylated (Fig. 2a). In line with
this, we found that the expression levels of miR-181c in-
creased after treatment (Fig. 2b and c), suggesting silen-
cing of the miR-181c by DNA methylation in glioblastoma
cells.
Interaction of CTCF with the regulatory region of
miR-181c
The region of the miR-181c occupied by CTCF in K562
cells as indicated by ENCODE data, spans the 7th, 13th
and 14th CpGs of the analyzed CpG-island (Fig. 2a). Im-
portantly, methylation levels of these CpGs are different
between T98G and U87MG cells (Fig. 2a arrowheads).
In particular the 7th and 14th CpGs show a 45 and
61.6 % increase in DNA methylation, in T98G as com-
pared to U87MG, opening the possibility that DNA
methylation may affect CTCF binding in this region.
Analysis of ChIP-seq data from ENCODE shows inter-
action of CTCF with the promoter region of miR-181c
in 23 of the 47 cell lines analyzed, suggesting cell-type
specific binding of CTCF to this region. However, if
CTCF interacts with the miR-181c promoter in the
glioblastoma cell lines used in this study is not known
(Additional file 1: Figure S1 and Table S1). To deter-
mine if CTCF interacts with the miR-181c promoter in
T98G and U87MG cells we performed chromatin im-
munoprecipitation (ChIP) (Fig. 3). As a positive control
we looked at CTCF enrichment on the human Igf2/H19











































































Fig. 2 DNA methylation of the miR-181c promoter region. a Scheme of the distribution of CpGs upstream the transcription start site and over the
gene body of miR-181c. DNA methylation profile of miR-181c promoter region in different cell types. The analyzed region is demarcated by the
black line upstream the transcription start site which represents a CpG island. A range of 8 to 12 independent clones were sequenced for each
cell type. Black circles represent methylated CpGs; white circles represent non-methylated CpGs. The black triangles point to the CpGs that
overlap with a CTCF binding motif and have a high level of methylation in T98G. b primiR-181c expression level in T98G cells and the T98G
treated with 5-aza-2′-deoxycytidine, measured by RT-qPCR with SYBR Green. c miR-181c expression level in T98G cells and T98G treated with
5-aza-2′-deoxycytidine, measured with Taqman assay. *p-value < 0.05; **p-value < 0.01
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[26, 41]. We found that CTCF interacts with the miR-
181c promoter in U87MG, but not in T98G cells
(Fig. 3). Motif analysis suggests that additional CTCF
binding sites are present over the gene body of miR-
181c, however, they are not bound by CTCF in
U87MG, T98G and K562 cells, as revealed by ChIP as-
says (Additional file 1: Figure S2).
The interaction of CTCF with the miR-181c promoter
correlates with moderate gene expression in U87MG
cells. Absence of CTCF interaction with the miR-181c
promoter correlates with DNA hypermethylation and
very low expression levels in T98G cells. Thus, CTCF
may be associated with expression regulation and pro-
tection against DNA methylation of the miR-181c pro-
moter in U87MG cells.
CTCF occupancy correlates with miR-181c expression
To further characterize the contribution of CTCF to miR-
181c regulation, CTCF was knocked down in U87MG cells
by transduction with a doxycycline inducible lentivirus
containing small-hairpin interference RNA (shRNAi)
against CTCF (Fig. 4 and Additional file 1: Figure S3).
Cells were treated with doxycycline or vehicle for 72 h and
the expression levels of primiR-181c and mature miR-181c
were assessed by RT-qPCR. MiR-181c was significantly
downregulated upon CTCF knockdown (Fig. 4b and c).
Doxycycline withdrawal for two weeks resulted in upregu-
lation of miR-181c (Fig. 4b and c). This data suggests that
CTCF promotes the expression of miR-181c in U87MG
cells.
CTCF depletion results in increased promoter methylation
and decreased expression of miR-181c
To test the function of CTCF in the protection against
DNA methylation of the miR-181c promoter we knocked
down CTCF in U87MG cells and assessed the level of
DNA methylation (Fig. 5a). After 5 days of transduction
with the CTCF shRNAi we observed a 20 % increase in
the DNA methylation level of the miR-181c promoter
region (Fig. 5b). This increase in DNA methylation was
accompanied with a reduction of primiR-181c and miR-
181c (Fig. 5c and d). These results suggest that CTCF
could protect the miR-181c promoter from DNA methy-
lation in U87MG cells.
miR-181c is flanked by two chromatin loops in GM12878
cells
The three-dimensional organization of the genome is
critical to establish proper programs of gene expression
through the formation of chromatin loops that bring to-
gether distal regulatory regions [42]. CTCF is a key me-
diator of chromatin looping, and novel techniques like
in situ Hi-C coupled with deep sequencing allow the
identification of all long-range chromatin interactions in
a given cell-type [43]. To gain insight on whether the
CTCF binding site in the promoter region of miR-181c
is implicated in loop formation we took advantage of
published data of high resolution in situ Hi-C generated
in GM12878 cells [43]. The in situ Hi-C data set repre-
sents the highest resolution (1 kb) map of chromatin in-
teractions ever published and identified chromatin loops
at a genome wide scale. In situ Hi-C data for GM12878
cells suggest the presence of two chromatin loops
(100 kb and 200 kb in size, respectively) flanking the
miR-181c locus and part of the Nanos3 locus (Fig. 6a).
The anchor sites for chromatin loops frequently overlap
with binding sites for CTCF in convergent orientation
(92 %) [43]. In fact, the anchor sites for the two chroma-
tin loops flanking the miR-181c locus correspond to
constitutive binding sites for CTCF in convergent orien-
tation (Fig. 6b). In contrast, the CTCF binding site on
the promoter region of miR-181c, which is occupied only
in a subset of cell lines, is not involved in chromatin












































Fig. 3 In vivo CTCF binding to the promoter region of the miR-181c.
Chromatin immunoprecipitation against CTCF in U87MG, T98G
glioblastoma cells and K562 erythroleukemic cells are shown. The
enrichment was evaluated in what we designated as the CTCF-upstream
and the CTCF-downstream predicted sites in relation to the
transcription start site of primiR-181c. The black arrows of the
scheme show the location of primers used for PCR amplification.
The linear range of Input DNA amplification products is shown.
Igf2/H19 DMR was used as a positive control for CTCF in vivo
enrichment. This set of data is representative of at least three
independent experiments
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promoter region of miR-181c protects against DNA
methylation, and we speculate that this particular site
does not participate in chromatin looping.
Depletion of CTCF in glioblastoma cells affects the
expression levels of NOTCH2
Our results suggest that CTCF participates in the tran-
scriptional regulation of miR-181c by protecting its pro-
moter against silencing by DNA methylation in
U87MG cells. Therefore, we asked if reduced levels of
CTCF could affect the transcript levels of miR-181c
targets like NOTCH2 [34]. We infected the glioblast-
oma U87MG cell line with a lentivirus expressing a
doxycycline inducible shRNAi against human CTCF.
Quantitative RT-PCR of NOTCH2 was performed after
3 and 30 days of induction with doxycycline. Knock-
down of CTCF at 3 days after induction results in an
increase of NOTCH2 mRNA (Fig. 7a). This trend is
more evident with cells that have been on doxycycline
during 30 days. Therefore CTCF loss causes the epi-
genetic silencing of miR-181c by DNA methylation
and the inability of the miR-181c to diminish the
A
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Fig. 4 Inducible knockdown of human CTCF in U87MG glioblastoma cell line affects miR-181c expression. a Western blot shows CTCF protein
levels in U87MG cells transduced with an inducible Empty Vector (EV) with and without Doxycycline (DOX) induction as controls. U87MG cells
were also transduced with an inducible shRNAi against CTCF without (−DOX) and with (+DOX) Doxycycline (DOX). b primiR-181c expression
levels in cell pools containing the inducible shRNAi against CTCF. No treatment (U87MG/shRNAi), treatment (U87MG/shRNAi/+DOX) and 2 weeks
after Doxycycline deprivation (U87MG/shRNAi/2 weeks/post-DOX) were measured by RT-qPCR with SYBR Green. Empty vector controls are shown
(U87MG/EV-DOX and U87MG/EV + DOX). N.S., not significant. c The miR-181c expression levels were evaluated under the same experimental conditions
as in (b) using the Taqman assay. *p-value < 0.05 and **p-value < 0.01
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levels of NOTCH2 transcripts in glioblastoma U87MG
cells (Fig. 7b).
Discussion
Cancer is a multistep disease that includes many inter-
dependent components at the cellular level [44]. There
are also molecular components that include genotypic
abnormalities but more recently epigenotypic deregula-
tion [45]. In particular, and based on the relevance of
the post-transcriptional regulatory function of micro-
RNAs over different types of genes we studied here how
epigenetic regulatory processes can dysregulate micro-
RNAs transcription in cancer. We asked how a micro-
RNA, the miR-181c, involved in the regulation of brain
specific genes can be epigenetically deregulated in glio-
blastoma cell lines, one of the more frequently occurring
primary malignant brain tumours. We focused on the
glioblastoma cell lines, T98G and U87MG, were the
miR-181c is downregulated in comparison to normal
brain tissues. This microRNA loss of gene expression
correlated with a strong gain of DNA methylation in the
miR-181c promoter region. Importantly, this aberrant
DNA hypermethylation apparently interferes with the
binding of the chromatin associated CTCF nuclear fac-
tor. CTCF depletion confirmed a gain of DNA methyla-
tion in U87MG cells supporting a previously reported
protective role of CTCF in tumour suppressor genes
[25]. Finally, CTCF knockdown induces the upregulation
of NOTCH2 a target of miR-181c.
Concerning the transcriptional regulation of micro-
RNAs an important sub-group is annotated as inter-
genic, but others are intronic and/or exonic, either in
sense or antisense orientations presenting a more com-
plex regulatory context. Genetic disruption of micro-
RNAs has been documented in cancer, but there are
some evidences that suggest that epigenetic alterations
can be one of the major mechanisms for microRNA de-
regulation in cancer and other diseases [2]. There is a
growing list of microRNAs that are subjected to epigen-
etic abnormal influence, including gain or loss of DNA
methylation, histone covalent modifications, and more
recently, the topological organization of the genome (see
below). For example, it is well documented how mem-
bers of the miR-34 family are involved in cancer through
cell cycle arrest, cell invasion, apoptosis or even cancer
metastasis [2]. These microRNAs are mainly silenced by
DNA methylation of their promoter regions. Concerning
the role of CTCF in microRNAs, a recent report showed
that the miR-125b1 is aberrantly silenced by DNA
methylation in breast cancer cells [30]. In such context,
CTCF binding to the promoter region of the miR-125b1
is disrupted and a gain in the repressive histone modifi-




























































Fig. 5 CTCF depletion results in increased promoter methylation and decreased expression of miR-181c. a Western-blot showing the levels of
CTCF protein in cells infected by a lentiviral system expressing a shRNAi against CTCF. b Comparative DNA methylation analysis of the miR-181c
promoter region. The percentage of methylated CpGs is shown for knockdown cells (U87MG-kd) and control cells (U87MG-ev). Black circles
correspond to methylated CpGs and white circles to unmethylated CpGs. c primiR-181c expression levels measured by RT-qPCR with SYBR
Green. d miR-181c expression levels measured by Taqman Assay. **p-value < 0.01
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cells [30]. Interestingly, alternative epigenetic silencing
mechanisms exist, like the overexpression of EZH2, a
key member of the Repressive Polycomb Complex,
PRC2, that in addition to silence many genes, including
tumour suppressor genes, can also silence different
microRNAs in cancer cells [46]. It has been documented
by several research groups that EZH2 is overexpressed
in different cancers, and found to repress abnormally
different microRNAs, including the miR-181c in prostate
and breast cancer cells [47]. Then, based on our obser-
vation and the differential binding of CTCF to the miR-
181c in different cell-types we propose that EZH2 and
Polycomb proteins may be responsible for silencing the
miR-181c in cell-types were the miR-181c is normally
not expressed, like in the human erythroleukemic K562
cells or primary lymphocytes (Fig. 1).
An important aspect that is to a certain extent under-
estimated is the possibility that in glioblastoma cells
CTCF is affected by mutations. Nowadays, there is a
repertoire of different CTCF mutations, comprising
somatic mutations, resulting in nonsense, missense,
frameshift and splice site mutations [48]. Some of these
mutations have been identified in different cancer
types. From a functional point of view, a large propor-
tion of mutations are found in the zinc-fingers that are
critical for CTCF binding to DNA [48, 49]. Therefore,
in glioblastoma cells and in regulatory regions as for
the miR-181c, CTCF disruption can be caused by spe-
cific mutations that affect its binding to DNA. This
view is further supported by a recent report in which
ctcf hemizygous knockout mice predisposes to cancer,
under certain inducible conditions, promoting tumour
Fig. 6 Two chromatin loops flank miR-181c in GM12878 cells. a Screenshot from JuiceBox in situ Hi-C data display of GM12878 cell line at 5 kb
resolution. Yellow triangles represent chromatin loops. MiR-181c is represented by an arrow. Note that miR-181c as well as its promoter and CTCF
proximal binding site are located in the transition between two chromatin loops. Left loop, chr19: 13855001–13975000; Right loop, chr19:
13990001–14185000. b IGV genome browser screenshot for ChIP-seq data of CTCF in 12 different cell lines. Signal tracks are displayed for each
cell line. Two constitutive binding sites of CTCF flank the dynamic CTCF binding site for miR-181C. The constitutive sites correspond to the anchors of
the chromatin loops as shown in (a). Data downloaded from the Analysis Data hub by the ENCODE project. c Model of two chromatin loops
flanking miR-181c
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aggressive invasion and metastatic dissemination [50].
What is even more relevant, in the context of the
present study, is the fact that CTCF haploinsufficient
mice destabilize genome-wide DNA methylation pat-
terns supporting the relationship between CTCF and
DNA methylation in certain genomic regions [50]. In
the same study point mutations have been correlated
with abnormal gain of DNA methylation. Therefore,
CTCF is now considered as a tumour suppressor gene
in human cancers and is significantly mutated gene in
different types of cancers [50, 51].
Based on the recent series of publications and given
the architectural role attributed to CTCF we cannot dis-
card, that the CTCF located in the promoter region of
the miR-181c plays a structural role [52]. Due to this
possibility we analyzed the genomic distribution of
CTCF, and its relationship with the three-dimensional
architecture of the genome taking advantage of the
newly, high resolution, genome-wide mapping of chro-
matin loops by in situ Hi-C [43]. In situ Hi-C series of
experiments have reached up to 1 kb resolution. As
shown in Fig. 6, the CTCF site associated with the miR-
181c promoter does not seem to correspond to a loop
anchor site (Fig. 6c). We believe that this is relevant,
and we propose that this CTCF site is not a structural
one, instead we suggest a local regulatory function, in
particular, protection against DNA methylation. In
addition, Lieberman Aiden and collaborators demon-
strated that more than 90 % of the CTCF sites at
loop anchors, at the DNA binding sequence level, are
positioned in a convergent orientation [43]. This is
extremely relevant since this type of sequence conver-
gence orientation for CTCF binding sites turns out to
be an excellent predictor of chromatin loop forma-
tion. Based in such prediction we propose a model in
which the miR-181c, and its adjacent gene Nanos3,
are not included in a loop and their location corres-
pond to a genomic region between two large chromo-
somal loops (Fig. 6c).
In glioblastoma the Notch signaling pathway is aber-
rantly activated [53]. NOTCH2 is one of the receptors of
the Notch pathway and was recently shown to be im-
portant for proliferation, invasion and self-renewal of
glioblastoma U87MG cells [34]. The NOTCH2 gene is
also a post-transcriptionally target of miR-181c and a
negative correlation between NOTCH2 gene expression
and miR-181c was found in glioblastoma samples [34].
In the present study we observed that CTCF knockdown
induces overexpression of NOTCH2 gene in U87MG
glioblastoma cells possibly as a consequence of the epi-
genetic silencing by DNA methylation of miR-181c














































Fig. 7 Depletion of CTCF in U87MG cells affects the transcription levels of NOTCH2. a NOTCH2 mRNA levels in U87MG cells transduced with an
inducible shRNAi against CTCF after 3 and 30 days with or without DOX induction (3d shRNAi-DOX; 3d shRNAi + DOX; 30d shRNAi-DOX; 30d
shRNAi + DOX). Empty vector controls are shown (3d EV-DOX and 3d EV + DOX). *p-value < 0.05. N.S., not significant. This set of data is representative
of three-independent experiments. b In U87MG cells CTCF binds to the promoter region of miR-181c (Left). Loss of CTCF causes epigenetic silencing of
miR-181c by DNA methylation and an increase of NOTCH2 mRNA (Right)
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CTCF as a regulator of gene expression for tumour sup-
pressor genes. In conclusion, microRNAs are subjected
to multiple levels of regulation and there are few exam-
ples of how they are regulated transcriptionally, and
even fewer how they are deregulated epigenetically. Due
to their critical role during animal development it is im-
portant to continue exploring how these regulatory
genes are controlled by a multitude of mechanisms.
Conclusions
Cancer is a disease that combines genetic and epigenetic
defects, in addition, to an active participation of micro-
RNAs. The biogenesis and ways of action of microRNAs
are relatively well known but their transcriptional regu-
lation is an aspect that is poorly understood. Here we
show that the miR-181c is differentially expressed in
glioblastoma cell lines. As seen in some tumour suppres-
sor genes CTCF is found in promoter regions protecting
them against epigenetic silencing. The absence of CTCF
correlates with gain of DNA methylation and the down-
regulation of the miR-181c expression. Our results sup-
port the epigenetic role of CTCF in the regulation of
microRNAs implicated in tumorigenesis.
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